|   |
|--------|

----

|   | x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|---|-----------------------------------------------------------------------------------------|

|   |  ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|--------|--------|------------------------------------------------------------------------------------------|

|   | Delaware                        |   | 36-4296006          |   |
|--------|---------------------------------|--------|---------------------|--------|
|   | (State or Other Jurisdiction of |   | (I.R.S. Employer    |   |
|   | Incorporation or Organization)  |   | Identification No.) |   |

| (Address of Principal Executive Offices) |
|------------------------------------------|

| (312) 222-9550 |
|----------------|

----

| Large Accelerated Filer   ̈ | Accelerated Filer o         |
|-------------------------------------------|-----------------------------|
|                                      |                        |
| Non-Accelerated Filer   ̈   | Smaller Reporting Company x |

|   |
|--------|

----

|                                                                                                                        |                                                                                        | Page   |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|--------|
| PART I.  – FINANCIAL INFORMATION                                                                            |                                                                                        |
|                                                                                                                        |                                                                                        |   |
| Item 1.                                                                                                                     | Financial Statements                                                                        |   |
|                                                                                                                        |                                                                                        |   |
| a) Condensed Consolidated Balance Sheets – March 31, 2011(unaudited) and December 31, 2010                            | 2                                                                                           |
|                                                                                                                        |                                                                                        |
| b) Condensed Consolidated Statements of Operations — Three months ended March 31, 2011 and March 31, 2010 (unaudited) | 3                                                                                           |
|                                                                                                                        |                                                                                        |
| c) Condensed Consolidated Statements of Cash Flows — Three months ended March 31, 2011 and March 31, 2010 (unaudited) | 4                                                                                           |
|                                                                                                                        |                                                                                        |
| d) Notes to Condensed Consolidated Financial Statements (unaudited)                                                         | 5                                                                                           |
|                                                                                                                        |                                                                                        |   |
| Item 2.                                                                                                                     | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 11     |
|                                                                                                                        |                                                                                        |   |
| Item 4.                                                                                                                     | Controls and Procedures                                                                     | 15     |
|                                                                                                                        |                                                                                        |   |
| PART II. — OTHER INFORMATION                                                                                          |                                                                                        |
|                                                                                                                        |                                                                                        |   |
| Item 1.                                                                                                                     | Legal Proceedings                                                                           | 15     |
|                                                                                                                        |                                                                                        |   |
| Item 2.                                                                                                                     | Unregistered Sales of Equity Securities and Use of Proceeds                                 | 16     |
|                                                                                                                        |                                                                                        |   |
| Item 3.                                                                                                                     | Defaults upon Senior Securities                                                             | 16     |
|                                                                                                                        |                                                                                        |   |
| Item 6.                                                                                                                     | Exhibits                                                                                    | 16     |
|                                                                                                                        |                                                                                        |   |
| SIGNATURES                                                                                                                  | 17                                                                                          |
|                                                                                                                        |                                                                                        |   |
| EXHIBIT INDEX                                                                                                               | 18                                                                                          |
|                                                                                                                        |                                                                                        |   |
| Exhibit 31 Section 302 Certification                                                                                        |                                                                                        |
| Exhibit 32 Section 906 Certification                                                                                        |                                                                                        |

----

|                                                                                                                                                                                                                          |   | March 31, |    |   | December 31, |   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------|---------|--------|-------------------|--------|
|                                                                                                                                                                                                                          |   | 2011           |    |   |              | 2010*  |   |
|                                                                                                                                                                                                                          |   | (unaudited)    |    |   |              |   |   |
| Assets                                                                                                                                                                                                                        |   |           |    |   |              |   |   |
| Current Assets:                                                                                                                                                                                                               |   |           |    |   |              |   |   |
| Cash and cash equivalents                                                                                                                                                                                                     |   | $              | — |   |              | $      | 13 |   |
| Accounts receivable                                                                                                                                                                                                           |   |           | 9       |   |              |   | 9 |   |
| Inventories                                                                                                                                                                                                                   |   |           | 108     |   |              |   | 108 |   |
| Prepaid expenses and other current assets                                                                                                                                                                                     |   |           | 20      |   |              |   | 25 |   |
| Total current assets                                                                                                                                                                                                          |   |           | 137     |   |              |   | 155 |   |
|                                                                                                                                                                                                                          |   |           |    |   |              |   |   |   |
| Fixed assets, net                                                                                                                                                                                                             |   |           | 957     |   |              |   | 1,055 |   |
| Licenses, patents and technology, net of amortization                                                                                                                                                                         |   |           | 37      |   |              |   | 62 |   |
| Inventories, non-current                                                                                                                                                                                                      |   |           | 785     |   |              |   | 785 |   |
| Total assets                                                                                                                                                                                                                  |   | $              | 1,916   |   |              | $      | 2,057 |   |
|                                                                                                                                                                                                                          |   |           |    |   |              |   |   |   |
| Liabilities and Stockholders’ Deficit                                                                                                                                                                                   |   |           |    |   |              |   |   |   |
| Current Liabilities:                                                                                                                                                                                                          |   |           |    |   |              |   |   |   |
| Checks issued in excess of amounts on deposit                                                                                                                                                                                 |   | $              | 12      |   |              | $      | — |   |
| Accounts payable                                                                                                                                                                                                              |   |           | 1,695   |   |              |   | 1,765 |   |
| Accrued payroll costs                                                                                                                                                                                                         |   |           | 1,521   |   |              |   | 1,395 |   |
| Advances payable to related parties                                                                                                                                                                                           |   |           | 2,001   |   |              |   | 1,766 |   |
| Accrued expenses                                                                                                                                                                                                              |   |           | 617     |   |              |   | 597 |   |
| Derivative liability                                                                                                                                                                                                          |   |           | 50      |   |              |   | 99 |   |
| Notes payable                                                                                                                                                                                                                 |   |           | 134     |   |              |   | 175 |   |
| Total current liabilities                                                                                                                                                                                                     |   |           | 6,030   |   |              |   | 5,797 |   |
|                                                                                                                                                                                                                          |   |           |    |   |              |   |   |   |
| Stockholders’ Deficit:                                                                                                                                                                                                  |   |           |    |   |              |   |   |   |
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 373,555 shares issued and outstanding at March 31, 2011 and December 31, 2010 (Liquidation value of all classes of preferred stock $2,876 at March 31, 2011) |   |           | 1,492   |   |              |   | 1,492 |   |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 52,109,570 and 48,379,042 shares issued and 52,090,361 and 48,359,833 shares outstanding at March 31, 2011 and December 31, 2010, respectively                 |   |           | 52      |   |              |   | 48 |   |
| Additional paid-in-capital                                                                                                                                                                                                    |   |           | 92,693  |   |              |   | 92,572 |   |
| Treasury stock: 19,209 shares at March 31, 2011 and December 31, 2010                                                                                                                                                         |   |           | (327    | )      |              |   | (327 | ) |
| Accumulated deficit                                                                                                                                                                                                           |   |           | (97,946 | )      |              |   | (97,448 | ) |
| Accumulated comprehensive loss—                                                                                                                                                                                         |   |           |    |   |              |   |   |   |
| Cumulative translation adjustment                                                                                                                                                                                             |   |           | (78     | )      |              |   | (77 | ) |
| Total stockholders’ deficit                                                                                                                                                                                             |   |           | (4,114  | )      |              |   | (3,740 | ) |
| Total liabilities and stockholders’ deficit                                                                                                                                                                             |   | $              | 1,916   |   |              | $      | 2,057 |   |

----

|                                                                                                        |   | Three Months Ended |       |
|-------------------------------------------------------------------------------------------------------------|--------|------------------------------|------------|
|                                                                                                        |   | March 31,               |       |
|                                                                                                        |   | 2011                         |       |   | 2010 |   |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Net sales                                                                                                   |   | $                            | 7          |   |   | $ | 8 |   |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Operating expenses                                                                                          |   |                         |       |   |   |   |   |   |
| Cost of revenues                                                                                            |   |                         | —    |   |   |   | — |   |
| Research and development, (net of settlement of trade debt of $15 for the three months ended March 31, 2011 |   |                         | 51         |   |   |   | 65 |   |
| Selling, general, and administrative                                                                        |   |                         | 422        |   |   |   | 499 |   |
| Total operating expenses                                                                                    |   |                         | 473        |   |   |   | 564 |   |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Operating loss                                                                                              |   |                         | (466       | ) |   |   | (556 | ) |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Other income (expense):                                                                                     |   |                         |       |   |   |   |   |   |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Benefit from derivative liability                                                                           |   |                         | 13         |   |   |   | 89 |   |
| Interest expense – related party                                                                      |   |                         | (38        | ) |   |   | — |   |
| Interest expense                                                                                            |   |                         | (7         | ) |   |   | (2 | ) |
| Total other income (expense)                                                                                |   |                         | (32        | ) |   |   | 87 |   |
| Net loss                                                                                                    |   |                         | (498       | ) |   |   | (469 | ) |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Preferred stock dividend                                                                                    |   |                         | (65        | ) |   |   | (65 | ) |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Net loss applicable to common stockholders                                                                  |   | $                            | (563       | ) |   | $ | (534 | ) |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Basic and diluted net loss per common share                                                                 |   | $                            | (0.01      | ) |   | $ | (0.01 | ) |
|                                                                                                        |   |                         |       |   |   |   |   |   |
| Weighed average number of common shares outstanding                                                         |   |                         | 49,436,617 |   |   |   | 43,385,041 |   |

----

|                                                                        |   | Three Months Ended |    |
|-----------------------------------------------------------------------------|--------|------------------------------|---------|
|                                                                        |   | March 31,               |    |
|                                                                        |   | 2011                         |    |   | 2010 |   |
|                                                                        |   |                         |    |   |   |   |
| Operating Activities:                                                       |   |                         |    |   |   |   |
| Net loss                                                                    |   | $                            | (498    | ) |   | $ | (469 | ) |
| Adjustments to reconcile net loss to net cash used in operating activities: |   |                         |    |   |   |   |   |   |
| Depreciation and amortization                                               |   |                         | 122     |   |   |   | 124 |   |
| Stock issued to non-employees for services                                  |   |                         | — |   |   |   | 6 |   |
| Benefit from derivative liability                                           |   |                         | (13     | ) |   |   | (89 | ) |
| Interest expense imputed on related party advances                          |   |                         | 38      |   |   |   | — |   |
| Common stock issued for services                                            |   |                         | 21      |   |   |   | — |   |
| Gain on settlement of trade indebtedness                                    |   |                         | (15     | ) |   |   | — |   |
| Changes in assets and liabilities:                                          |   |                         |    |   |   |   |   |   |
| Checks issued in excess of amounts on deposit                               |   |                         | 12      |   |   |   | (5 | ) |
| Accounts receivable                                                         |   |                         | 1       |   |   |   | 6 |   |
| Inventories                                                                 |   |                         | — |   |   |   | 1 |   |
| Prepaid expenses and other current assets                                   |   |                         | 5       |   |   |   | 16 |   |
| Accounts payable                                                            |   |                         | (55     | ) |   |   | 47 |   |
| Accrued expenses                                                            |   |                         | 146     |   |   |   | 191 |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Net cash used in operating activities                                       |   |                         | (236    | ) |   |   | (172 | ) |
|                                                                        |   |                         |    |   |   |   |   |   |
| Investing activities:                                                       |   |                         |    |   |   |   |   |   |
| Net cash used in investing activities                                       |   |                         | — |   |   |   | — |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Financing activities:                                                       |   |                         |    |   |   |   |   |   |
| Proceeds from related parties                                               |   |                         | 235     |   |   |   | 115 |   |
| Proceeds from issuance of convertible note                                  |   |                         | — |   |   |   | 75 |   |
| Repayment of notes                                                          |   |                         | (12     | ) |   |   | — |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Net cash provided by financing activities                                   |   |                         | 223     |   |   |   | 190 |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Net increase (decrease) in cash and cash equivalents                        |   |                         | (13     | ) |   |   | 18 |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Cash and cash equivalents at the beginning of period                        |   |                         | 13      |   |   |   | — |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Cash and cash equivalents at end of period                                  |   | $                            | — |   |   | $ | 18 |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Supplemental disclosure of cash flow information:                           |   |                         |    |   |   |   |   |   |
|                                                                        |   |                         |    |   |   |   |   |   |
| Non-cash transactions during the period for:                                |   |                         |    |   |   |   |   |   |
| Issuance of common stock and warrants in settlement of a lawsuit            |   | $                            | — |   |   | $ | 538 |   |
| Reduction of derivative liability                                           |   |                         | 36      |   |   |   | — |   |
| Stock issuable for accrued liability                                        |   |                         | — |   |   |   | 30 |   |

----

|                                                                   |   | Three months ended |       |
|------------------------------------------------------------------------|--------|------------------------------|------------|
|                                                                   |   | March 31,               |       |
|                                                                   |   | 2011                         |       |   | 2010 |   |
|                                                                   |   | (Unaudited)                  |       |
|                                                                   |   |                         |       |   |   |   |
| Net loss applicable to common stockholders                             |   | $                            | (563       | ) |   | $ | (534 | ) |
| Foreign currency adjustment                                            |   |                         | (1         | ) |   |   | — |   |
| Comprehensive net loss applicable to common stockholders               |   | $                            | (564       | ) |   | $ | (534 | ) |
| Basic and diluted comprehensive net loss per common share              |   | $                            | (0.01      | ) |   | $ | (0.01 | ) |
| Basic and diluted weighted average number of common shares outstanding |   |                         | 49,436,617 |   |   |   | 43,385,041 |   |

----

|                        |   | March 31, |   |   | December 31, |   |
|-----------------------------|--------|----------------|--------|--------|-------------------|--------|
|                        |   | 2011           |   |   | 2010              |   |
|                        |   | (unaudited)    |   |   |              |   |
|                        |   |           |   |   |              |   |
| Purchased parts             |   | $              | 269    |   |              | $      | 269 |   |
| Finished goods              |   |           | 624    |   |              |   | 624 |   |
| Total inventory             |   |           | 893    |   |              |   | 893 |   |
| Less: inventory non-current |   |           | 785    |   |              |   | 785 |   |
| Total inventory current     |   | $              | 108    |   |              | $      | 108 |   |

| Note 4. | Fixed Assets |
|--------------|--------------|

|                                           |   | March 31, |   |   | December 31, |   |
|------------------------------------------------|--------|----------------|--------|--------|-------------------|--------|
|                                           |   | 2011           |   |   | 2010              |   |
|                                           |   | (unaudited)    |   |   |              |   |
|                                           |   |           |   |   |              |   |
| Furniture and fixtures                         |   | $              | 47     |   |              | $      | 47 |   |
| Laboratory equipment                           |   |           | 508    |   |              |   | 508 |   |
| Computer and communications equipment          |   |           | 261    |   |              |   | 261 |   |
| Design and tooling                             |   |           | 1,204  |   |              |   | 1,204 |   |
| Machinery and equipment                        |   |           | 777    |   |              |   | 777 |   |
|                                           |   |           | 2,797  |   |              |   | 2,797 |   |
| Less accumulated depreciation and amortization |   |           | (1,840 | )      |              |   | (1,742 | ) |
| Total                                          |   | $              | 957    |   |              | $      | 1,055 |   |

|                          |   | March 31, |   |   | December 31, |   |
|-------------------------------|--------|----------------|--------|--------|-------------------|--------|
|                          |   | 2011           |   |   | 2010              |   |
|                          |   | (unaudited)    |   |   |              |   |
|                          |   |           |   |   |              |   |
| Licenses                      |   | $              | 320    |   |              | $      | 320 |   |
|                          |   |           |   |   |              |   |   |   |
| Patent costs                  |   |           | 133    |   |              |   | 133 |   |
| LabCorp Technology Agreement  |   |           | 260    |   |              |   | 260 |   |
|                          |   |           | 713    |   |              |   | 713 |   |
| Less accumulated amortization |   |           | (676   | )      |              |   | (651 | ) |
| Total                         |   | $              | 37     |   |              | $      | 62 |   |

----

|                              |   | March 31, |   |   | December 31, |   |
|-----------------------------------|--------|----------------|--------|--------|-------------------|--------|
|                              |   | 2011           |   |   | 2010              |   |
|                              |   | (unaudited)    |   |   |              |   |
|                              |   |           |   |   |              |   |
| Accrued interest                  |   | $              | 61     |   |              | $      | 60 |   |
| Accrued franchise and other taxes |   |           | 295    |   |              |   | 268 |   |
| Accrued compensation              |   |           | 105    |   |              |   | 90 |   |
| Other accrued expenses            |   |           | 156    |   |              |   | 179 |   |
| Total                             |   | $              | 617    |   |              | $      | 597 |   |

|                                                                                                                                                                                                       |   | March 31, |   |   | December 31, |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------|--------|--------|-------------------|--------|
|                                                                                                                                                                                                       |   | 2011           |   |   | 2010              |   |
|                                                                                                                                                                                                       |   | (Unaudited)    |   |   |              |   |
|                                                                                                                                                                                                       |   |           |   |   |              |   |
| Asher Enterprises, Inc., $75,000 Convertible Promissory Note issued March 9, 2010; interest rate 8% per annum, due December 10, 2010                                                                       |   | $              | 26     |   |              | $      | 56 |   |
|                                                                                                                                                                                                       |   |           |   |   |              |   |   |   |
| White, White & Van Etten PC, $68,750 non-interest bearing Promissory Note issued September 30, 2010; payable in eleven equal payments of $6,250; interest imputed at 5% per annum, due August 24, 2011 |   |           | 38     |   |              |   | 49 |   |
|                                                                                                                                                                                                       |   |           |   |   |              |   |   |   |
| Robert Shaw, $25,000 Promissory Note issued September 20, 2001; interest rate 9% per annum, due December 20, 2001                                                                                          |   |           | 15     |   |              |   | 15 |   |
|                                                                                                                                                                                                       |   |           |   |   |              |   |   |   |
| Ventana Medical Systems, Inc. $62,946 Promissory Note issued November 30, 2003; due December 31, 2003; interest rate 8% per annum payable after December 31, 2003                                          |   |           | 21     |   |              |   | 21 |   |
|                                                                                                                                                                                                       |   |           |   |   |              |   |   |   |
| Xillix Technologies Corporation $361,000 Promissory Note issued June 26, 1998; Interest rate Canadian Prime plus 6% per annum, due December 27, 1999; represents a debt of AccuMed                         |   |           | 34     |   |              |   | 34 |   |
|                                                                                                                                                                                                       |   | $              | 134    |   |              | $      | 175 |   |

----

|                                                     |   | March 31, |       |   | March 31,    |   |
|----------------------------------------------------------|--------|----------------|------------|--------|-------------------|--------|
|                                                     |   | 2011           |       |   | 2010              |   |
|                                                     |   | (unaudited)    |       |   | (unaudited)  |   |
| Basic and Diluted:                                       |   |           |       |   |              |   |
| Net loss applicable to common stockholder (in thousands) |   | $              | (563       | )      |              | $      | (534 | ) |
| Weighted average common shares outstanding               |   |           | 49,436,617 |   |              |   | 43,385,041 |   |
| Net loss per common share                                |   | $              | (0.01      | )      |              | $      | (0.01 | ) |

|                                          |   | March 31,                |    |   | December 31,             |   |
|-----------------------------------------------|--------|-------------------------------|---------|--------|-------------------------------|--------|
|                                          |   | 2011                          |    |   | 2010                          |   |
|                                          |   | Shares Issued & |    |   | Shares Issued & |   |
| Offering                                      |   | Outstanding                   |    |   | Outstanding                   |   |
|                                          |   | (unaudited)                   |    |   |                          |   |
|                                          |   |                          |    |   |                          |   |
| Series A convertible                          |   |                          | 47,250  |   |                          |   | 47,250 |   |
| Series B convertible, 10% cumulative dividend |   |                          | 93,750  |   |                          |   | 93,750 |   |
| Series C convertible, 10% cumulative dividend |   |                          | 38,333  |   |                          |   | 38,333 |   |
| Series D convertible, 10% cumulative dividend |   |                          | 175,000 |   |                          |   | 175,000 |   |
| Series E convertible, 10% cumulative dividend |   |                          | 19,222  |   |                          |   | 19,222 |   |
| Total Preferred Stock                         |   |                          | 373,555 |   |                          |   | 373,555 |   |

----

| Series A Convertible Preferred Stock                                             |
|----------------------------------------------------------------------------------|
| Liquidation Value:                                                               | $4.50 per share, $212,625 |
| Conversion Price:                                                                | $103.034 per share |
| Conversion Rate:                                                                 | 0.04367—Liquidation Value divided by Conversion Price ($4.50/$103.034) |
| Voting Rights:                                                                   | None |
| Dividends:                                                                       | None |
| Conversion Period:                                                               | Any time |
|                                                                             |   |
| Series B Convertible Preferred Stock                                             |
| Liquidation Value:                                                               | $4.00 per share, $375,000 |
| Conversion Price:                                                                | $10.00 per share |
| Conversion Rate:                                                                 | 0.40—Liquidation Value divided by Conversion Price ($4.00/$10.00) |
| Voting Rights:                                                                   | None |
| Dividends:                                                                       | 10%—Quarterly—Commencing March 31, 2001 |
| Conversion Period:                                                               | Any time |
| Cumulative and undeclared dividends in arrears at March 31, 2011 were $379,000   |
|                                                                             |   |
| Series C Convertible Preferred Stock                                             |
| Liquidation Value:                                                               | $3.00 per share, $115,000 |
| Conversion Price:                                                                | $6.00 per share |
| Conversion Rate:                                                                 | 0.50—Liquidation Value divided by Conversion Price ($3.00/$6.00) |
| Voting Rights:                                                                   | None |
| Dividends:                                                                       | 10%—Quarterly—Commencing March 31, 2002 |
| Conversion Period:                                                               | Any time |
| Cumulative and undeclared dividends in arrears at March 31, 2011 were $108,000   |
|                                                                             |   |
| Series D Convertible Preferred Stock                                             |
| Liquidation Value:                                                               | $10.00 per share, $1,750,000 |
| Conversion Price:                                                                | $10.00 per share |
| Conversion Rate:                                                                 | 1.00—Liquidation Value divided by Conversion Price ($10.00/$10.00) |
| Voting Rights:                                                                   | None |
| Dividends:                                                                       | 10%—Quarterly—Commencing April 30, 2002 |
| Conversion Period:                                                               | Any time |
| Cumulative and undeclared dividends in arrears at March 31, 2011 were $1,648,000 |
|                                                                             |   |
| Series E Convertible Preferred Stock                                             |
| Liquidation Value:                                                               | $22.00 per share, $422,888 |
| Conversion Price:                                                                | $8.00 per share |
| Conversion Rate:                                                                 | 2.75—Liquidation Value divided by Conversion Price ($22.00/$8.00) |
| Voting Rights:                                                                   | Equal in all respects to holders of common shares |
| Dividends:                                                                       | 10%—Quarterly—Commencing May 31, 2002 |
| Conversion Period:                                                               | Any time |
| Cumulative and undeclared dividends in arrears at March 31, 2011 were $401,000   |

----

|                                             |   | 2011   |              |   | 2010   |   |
|--------------------------------------------------|--------|--------|-------------------|--------|--------|--------|
| Expected volatility                              |   |   | 36%-402           | %      |   |   | 250 | % |
| Expected term (years)                            |   |   | 0.04 – 2.51 |   |   |   | 1.5 |   |
| Risk-free interest rate                          |   |   | 1.00              | %      |   |   | 1.00 | % |
| Expected dividend yield                          |   |   | 0                 | %      |   |   | 0 | % |
| Forfeiture rate                                  |   |   | 0                 | %      |   |   | 0 | % |
| Resulting weighted average grant date fair value |   | $      | 0.01              |   |   | $      | 0.15 |   |

----

----

----

----

----

----

| Exhibit |         |                                                                                                                                                                                                                                                       |
|---------|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number  |         | Description                                                                                                                                                                                                                                                |
|    |         |                                                                                                                                                                                                                                                       |
| 31.1    |         | Section 302 certification by principal executive and chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted  pursuant to Section 302 of the Sarbanes Oxley Act of 2002. |
|    |         |                                                                                                                                                                                                                                                       |
| 32.1    |    | Section 906 certification by principal executive and chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.                                                                     |

----

| CytoCore, Inc.                |
|-------------------------------|
|                          |
| /s/ Robert F. McCullough, Jr. |
| Robert F. McCullough, Jr.     |
| Chief Executive Officer and   |
| Chief Financial Officer       |

----

| Exhibit |         |                                                                                                                                                                                                                                            |
|---------|--------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number  |         | Description                                                                                                                                                                                                                                     |
|    |         |                                                                                                                                                                                                                                            |
| 31.1    |         | Section 302 certification by principal executive and chief financial officer pursuant to Rules 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002. |
|    |         |                                                                                                                                                                                                                                            |
| 32.1    |    | Section 906 certification by principal executive and chief financial officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.                                                          |

----